UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_____________

FORM 8-K
_____________

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934


Date of report (Date of earliest event reported): January 4, 2006

 
Keryx Biopharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)

 

Delaware
(State or Other Jurisdiction
of Incorporation)
000-30929
(Commission File Number)
13-4087132
(IRS Employer Identification No.)



750 Lexington Avenue
New York, New York 10022
(Address of Principal Executive Offices)

(212) 531-5965
(Registrant's telephone number, including area code)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

£  
Written communications pursuant to Rule 425 under the Securities Act.
£  
Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
£  
Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
£  
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

 

 
Item 5.02.  Departure of Directors or Principal Officers; Election of Directors;  Appointment of Principal Officers.

(d) On January 4, 2006, Dr. Jonathan Spicehandler was appointed to the Board of Directors of Keryx Biopharmaceuticals, Inc. (“Keryx”) by unanimous vote of the directors. There are no arrangements or understandings between Dr. Spicehandler and any other person pursuant to which Dr. Spicehandler was appointed to the Board. Since January 1, 2005, Dr. Spicehandler has not entered into any transaction in which he has a direct or indirect material interest and in which Keryx or any subsidiary of Keryx is also a party, and Dr. Spicehandler is not currently considering any such transactions. The text of a press release announcing the appointment of Dr. Spicehandler is attached as Exhibit 99.1 and is incorporated by reference into this Item.

Item 9.01. Financial Statements and Exhibits.

(c) Exhibits

The following exhibit is filed as a part of this report:

 
Exhibit
    
Number
Description
  
     
99.1
Press Release dated January 4, 2006.
 

 

 
SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


 
 
Keryx Biopharmaceuticals, Inc.
 
(Registrant)
   
   
   
Date: January 6, 2006
  
   
 
By:  /s/ Ron Bentsur                                
 
Ron Bentsur
 
Vice President Finance and
 
Investor Relations


 
INDEX TO EXHIBITS


 
Exhibit
   
Number
Description
  
     
99.1
Press Release dated January 4, 2006.
  
.